

# 2017-2022 Global and Japan Antitumor Drugs of Alkylating Agent Class Market Analysis Report

<https://marketpublishers.com/r/22F80C35FC5EN.html>

Date: August 2017

Pages: 103

Price: US\$ 3,085.00 (Single User License)

ID: 22F80C35FC5EN

## Abstracts

The global Antitumor Drugs of Alkylating Agent Class market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Antitumor Drugs of Alkylating Agent Class market's development status and future trend in the global and Japan. It splits Antitumor Drugs of Alkylating Agent Class market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include

OHARA Pharmaceutical Co.,Ltd.

Kyowa Hakko Kirin Co.,Ltd

Eisai Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Aspen Japan K.K.

Nippon Shinyaku Co., Ltd.

...

Geographically, this report splits the Global market into the following regions:

Asia Pacific

Japan

Tokyo

Yokohama

Osaka

Nagoya

Others

China

Korea

India

Others

Europe

France

Germany

United Kingdom

Italy

Russia

Others

North America

United States

Canada

Latin America

Brazil

Mexico

Others

Southeast Asia

Singapore

Malaysia

Vietnam

Myanmar

Thailand

Indonesia

Philippines

Others

Middle East & Africa

Saudi Arabia

Iran

UAE

Turkey

Israel

Egypt

South Africa

Others

On the basis of product, the Antitumor Drugs of Alkylating Agent Class market is primarily split into

#### Antitumor Drugs of Alkylating Agent Class Market, by Alkylating Agent Class

Bendamustine

Mizolastine

Busulfan

Embichine

Dacarbazine

Bepotastine

Carmustine

Melphalan

Nimustine

Lomustine

Chlorambucil

Estramustine

Altretamine

Fotemustine

### Key Applications

Department of Oncology

Department of Chemotherapy

Pharmacology

## Contents

### 1 ANTITUMOR DRUGS OF ALKYLATING AGENT CLASS OVERVIEW

#### 1.1 Product Overview and Scope of Antitumor Drugs of Alkylating Agent Class

#### 1.2 Global and Japan Antitumor Drugs of Alkylating Agent Class Market by Applications/End Users

##### 1.2.1 Japan Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share Comparison by Applications (2012-2017)

###### 1.2.1.1 Japan Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share by Applications (2012-2017)

###### 1.2.1.2 Japan Antitumor Drugs of Alkylating Agent Class Sales Growth Rate (%) by Applications (2012-2017)

###### 1.2.1.3 Market Drivers and Opportunities

##### 1.2.2 Japan Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share Comparison by Applications (2012-2017)

##### 1.2.3 Global Antitumor Drugs of Alkylating Agent Class Sales by Application (2012-2017)

###### 1.2.3.1 Global Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share by Applications (2012-2017)

###### 1.2.3.2 Global Antitumor Drugs of Alkylating Agent Class Sales Growth Rate (%) by Applications (2012-2017)

###### 1.2.3.3 Market Drivers and Opportunities

##### 1.2.4 Global Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share Comparison by Applications (2012-2017)

###### 1.2.5 Department of Oncology

###### 1.2.6 Department of Chemotherapy

###### 1.2.7 Pharmacology

#### 1.3 Global and Japan Market Size (Sales and Revenue) of Antitumor Drugs of Alkylating Agent Class (2012-2017)

##### 1.3.1 Japan Market Size (Sales and Revenue) of Antitumor Drugs of Alkylating Agent Class (2012-2017)

###### 1.3.1.1 Japan Antitumor Drugs of Alkylating Agent Class Sales ( ) and Growth Rate (%) (2012-2017)

###### 1.3.1.2 Japan Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Growth Rate (2012-2017)

##### 1.3.2 Global Market Size (Sales and Revenue) of Antitumor Drugs of Alkylating Agent Class (2012-2017)

###### 1.3.2.1 Global Antitumor Drugs of Alkylating Agent Class Sales ( ) and Growth Rate

(%) (2012-2017)

1.3.2.2 Global Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Growth Rate (2012-2017)

1.4 Global and Japan Classification of Antitumor Drugs of Alkylating Agent Class by Alkylating Agent Class

1.4.1 Japan Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share by Alkylating Agent Class (2012-2017)

1.4.2 Global Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share by Alkylating Agent Class (2012-2017)

1.4.3 Japan Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share by Alkylating Agent Class (2012-2017)

1.4.4 Global Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share by Alkylating Agent Class (2012-2017)

1.4.5 Japan Antitumor Drugs of Alkylating Agent Class Price ( ) by Alkylating Agent Class (2012-2017)

1.4.6 Global Antitumor Drugs of Alkylating Agent Class Price ( ) by Alkylating Agent Class (2012-2017)

1.4.7 Japan Antitumor Drugs of Alkylating Agent Class Sales Growth Rate (%) by Alkylating Agent Class (2012-2017)

1.4.8 Global Antitumor Drugs of Alkylating Agent Class Sales Growth Rate (%) by Alkylating Agent Class (2012-2017)

1.4.9 Bendamustine

1.4.10 Mizolastine

1.4.11 Busulfan

1.4.12 Embichine

1.4.13 Dacarbazine

Bepotastine

Carmustine

Melphalan

Nimustine

Lomustine

Chlorambucil

Estramustine

Altretamine

Fotemustine

## **2 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ALKYLATING AGENT CLASS MARKET COMPETITION BY PLAYERS/MANUFACTURERS**

## 2.1 Japan Antitumor Drugs of Alkylating Agent Class Market Competition by Players/Manufacturers

2.1.1 Japan Antitumor Drugs of Alkylating Agent Class Sales and Market Share of Key Players/Manufacturers (2012-2017)

2.1.2 Japan Antitumor Drugs of Alkylating Agent Class Revenue and Share by Players/Manufacturers (2012-2017)

2.1.3 Japan Antitumor Drugs of Alkylating Agent Class Average Price ( ) by Players/Manufacturers (2012-2017)

2.1.4 Japan Antitumor Drugs of Alkylating Agent Class Market Competitive Situation and Trends

2.1.4.1 Japan Antitumor Drugs of Alkylating Agent Class Market Concentration Rate

2.1.4.2 Japan Antitumor Drugs of Alkylating Agent Class Market Share of Top 3 and Top 5 Players/Manufacturers

2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market

2.1.5 Japan Players/Manufacturers Antitumor Drugs of Alkylating Agent Class Manufacturing Base Distribution, Sales Area, Product Types

## 2.2 Global Antitumor Drugs of Alkylating Agent Class Market Competition by Players/Manufacturers

2.2.1 Global Antitumor Drugs of Alkylating Agent Class Sales and Market Share of Key Players/Manufacturers (2012-2017)

2.2.2 Global Antitumor Drugs of Alkylating Agent Class Revenue and Share by Players/Manufacturers (2012-2017)

2.2.3 Global Antitumor Drugs of Alkylating Agent Class Average Price ( ) by Players/Manufacturers (2012-2017)

2.2.4 Global Antitumor Drugs of Alkylating Agent Class Market Competitive Situation and Trends

2.2.4.1 Global Antitumor Drugs of Alkylating Agent Class Market Concentration Rate

2.2.4.2 Global Antitumor Drugs of Alkylating Agent Class Market Share of Top 3 and Top 5 Players/Manufacturers

2.2.4.3 Mergers & Acquisitions, Expansion in Global Market

2.2.5 Global Players/Manufacturers Antitumor Drugs of Alkylating Agent Class Manufacturing Base Distribution, Sales Area, Product Types

## **3 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ALKYLATING AGENT CLASS SALES AND REVENUE BY REGIONS (2012-2017)**

### 3.1 Asia Pacific Antitumor Drugs of Alkylating Agent Class Sales and Revenue by Regions (2012-2017)

3.1.1 Japan Antitumor Drugs of Alkylating Agent Class Sales and Revenue



(2012-2017)

3.1.1.1 Japan Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.1.1.2 Japan Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.1.1.3 Japan Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.1.2 China Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.1.2.1 China Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.1.2.2 China Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.1.2.3 China Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.1.3 Korea Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.1.3.1 Korea Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.1.3.2 Korea Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.1.3.3 Korea Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.1.4 India Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.1.4.1 India Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.1.4.2 India Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.1.4.3 India Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.1.5 Others Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.1.5.1 Others Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.1.5.2 Others Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.1.5.3 Others Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.2 Europe Antitumor Drugs of Alkylating Agent Class Sales and Revenue by Regions (2012-2017)

3.2.1 France Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.2.1.1 France Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.2.1.2 France Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.2.1.3 France Antitumor Drugs of Alkylating Agent Class Price (€)(2012-2017)

3.2.2 Germany Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.2.2.1 Germany Antitumor Drugs of Alkylating Agent Class Sales (€) and Market Share (2012-2017)

3.2.2.2 Germany Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.2.2.3 Germany Antitumor Drugs of Alkylating Agent Class Price (€)(2012-2017)

3.2.3 United Kingdom Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.2.3.1 United Kingdom Antitumor Drugs of Alkylating Agent Class Sales (€) and Market Share (2012-2017)

3.2.3.2 United Kingdom Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.2.3.3 United Kingdom Antitumor Drugs of Alkylating Agent Class Price (€)(2012-2017)

3.2.4 Italy Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.2.4.1 Italy Antitumor Drugs of Alkylating Agent Class Sales (€) and Market Share (2012-2017)

3.2.4.2 Italy Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.2.4.3 Italy Antitumor Drugs of Alkylating Agent Class Price (€)(2012-2017)

3.2.5 Russia Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.2.5.1 Russia Antitumor Drugs of Alkylating Agent Class Sales (€) and Market Share (2012-2017)

3.2.5.2 Russia Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.2.5.3 Russia Antitumor Drugs of Alkylating Agent Class Price (€)(2012-2017)

3.2.6 Others Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.2.6.1 Others Antitumor Drugs of Alkylating Agent Class Sales (€) and Market Share (2012-2017)

3.2.6.2 Others Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.2.6.3 Others Antitumor Drugs of Alkylating Agent Class Price (€)(2012-2017)

3.3 North America Antitumor Drugs of Alkylating Agent Class Sales and Revenue by

## Regions (2012-2017)

### 3.3.1 United States Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.3.1.1 United States Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.3.1.2 United States Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.3.1.3 United States Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.3.2 Canada Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.3.2.1 Canada Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.3.2.2 Canada Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.3.2.3 Canada Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.4 Latin America Antitumor Drugs of Alkylating Agent Class Sales and Revenue by Regions (2012-2017)

#### 3.4.1 Brazil Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.4.1.1 Brazil Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.4.1.2 Brazil Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.4.1.3 Brazil Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

#### 3.4.2 Mexico Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.4.2.1 Mexico Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.4.2.2 Mexico Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.4.2.3 Mexico Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

#### 3.4.3 Others Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.4.3.1 Others Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.4.3.2 Others Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.4.3.3 Others Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.5 Southeast Asia Antitumor Drugs of Alkylating Agent Class Sales and Revenue by

## Regions (2012-2017)

### 3.5.1 Singapore Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.5.1.1 Singapore Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.5.1.2 Singapore Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.5.1.3 Singapore Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.5.2 Malaysia Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.5.2.1 Malaysia Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.5.2.2 Malaysia Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.5.2.3 Malaysia Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.5.3 Vietnam Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.5.3.1 Vietnam Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.5.3.2 Vietnam Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.5.3.3 Vietnam Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.5.4 Myanmar Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.5.4.1 Myanmar Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.5.4.2 Myanmar Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.5.4.3 Myanmar Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.5.5 Thailand Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.5.5.1 Thailand Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.5.5.2 Thailand Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.5.5.3 Thailand Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.5.6 Indonesia Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.5.6.1 Indonesia Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market

Share (2012-2017)

3.5.6.2 Indonesia Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.5.6.3 Indonesia Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.5.7 Philippines Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.5.7.1 Philippines Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.5.7.2 Philippines Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.5.7.3 Philippines Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.5.8 Others Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.5.8.1 Others Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.5.8.2 Others Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.5.8.3 Others Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.6 Middle East & Africa Antitumor Drugs of Alkylating Agent Class Sales and Revenue by Regions (2012-2017)

3.6.1 Saudi Arabia Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.6.1.1 Saudi Arabia Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.6.1.2 Saudi Arabia Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.6.1.3 Saudi Arabia Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.6.2 Iran Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.6.2.1 Iran Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.6.2.2 Iran Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.6.2.3 Iran Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

3.6.3 UAE Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

3.6.3.1 UAE Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

3.6.3.2 UAE Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

3.6.3.3 UAE Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)



### 3.6.4 Turkey Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.6.4.1 Turkey Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.6.4.2 Turkey Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.6.4.3 Turkey Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.6.5 Israel Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.6.5.1 Israel Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.6.5.2 Israel Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.6.5.3 Israel Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.6.6 Egypt Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.6.6.1 Egypt Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.6.6.2 Egypt Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.6.6.3 Egypt Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.6.7 South Africa Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.6.7.1 South Africa Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.6.7.2 South Africa Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.6.7.3 South Africa Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

### 3.6.8 Others Antitumor Drugs of Alkylating Agent Class Sales and Revenue (2012-2017)

#### 3.6.8.1 Others Antitumor Drugs of Alkylating Agent Class Sales ( ) and Market Share (2012-2017)

#### 3.6.8.2 Others Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Market Share (2012-2017)

#### 3.6.8.3 Others Antitumor Drugs of Alkylating Agent Class Price ( )(2012-2017)

## **4 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ALKYLATING AGENT CLASS PLAYERS/MANUFACTURERS PROFILES AND SALES DATA**

#### 4.1 OHARA Pharmaceutical Co.,Ltd.

##### 4.1.1 Company Basic Information, Manufacturing Base and Competitors

##### 4.1.2 Antitumor Drugs of Alkylating Agent Class Product Category, Application and Specification

###### 4.1.2.1 Product A

###### 4.1.2.2 Product B

##### 4.1.3 OHARA Pharmaceutical Co.,Ltd. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

##### 4.1.4 Main Business/Business Overview

#### 4.2 Kyowa Hakko Kirin Co.,Ltd

##### 4.2.1 Company Basic Information, Manufacturing Base and Competitors

##### 4.2.2 Antitumor Drugs of Alkylating Agent Class Product Category, Application and Specification

###### 4.2.2.1 Product A

###### 4.2.2.2 Product B

##### 4.2.3 Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

##### 4.2.4 Main Business/Business Overview

#### 4.3 Eisai Co., Ltd.

##### 4.3.1 Company Basic Information, Manufacturing Base and Competitors

##### 4.3.2 Antitumor Drugs of Alkylating Agent Class Product Category, Application and Specification

###### 4.3.2.1 Product A

###### 4.3.2.2 Product B

##### 4.3.3 Eisai Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

##### 4.3.4 Main Business/Business Overview

#### 4.4 Mitsubishi Tanabe Pharma Corporation

##### 4.4.1 Company Basic Information, Manufacturing Base and Competitors

##### 4.4.2 Antitumor Drugs of Alkylating Agent Class Product Category, Application and Specification

###### 4.4.2.1 Product A

###### 4.4.2.2 Product B

##### 4.4.3 Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

##### 4.4.4 Main Business/Business Overview

#### 4.5 Aspen Japan K.K.

##### 4.5.1 Company Basic Information, Manufacturing Base and Competitors

##### 4.5.2 Antitumor Drugs of Alkylating Agent Class Product Category, Application and

## Specification

### 4.5.2.1 Product A

### 4.5.2.2 Product B

4.5.3 Aspen Japan K.K. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

### 4.5.4 Main Business/Business Overview

## 4.6 Nippon Shinyaku Co., Ltd.

### 4.6.1 Company Basic Information, Manufacturing Base and Competitors

4.6.2 Antitumor Drugs of Alkylating Agent Class Product Category, Application and Specification

### 4.6.2.1 Product A

### 4.6.2.2 Product B

4.6.3 Nippon Shinyaku Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

### 4.6.4 Main Business/Business Overview

...

## **5 ANTITUMOR DRUGS OF ALKYLATING AGENT CLASS MANUFACTURING COST ANALYSIS**

### 5.1 Antitumor Drugs of Alkylating Agent Class Key Raw Materials Analysis

#### 5.1.1 Key Raw Materials

#### 5.1.2 Price Trend of Key Raw Materials

#### 5.1.3 Key Suppliers of Raw Materials

#### 5.1.4 Market Concentration Rate of Raw Materials

### 5.2 Proportion of Manufacturing Cost Structure

#### 5.2.1 Raw Materials

#### 5.2.2 Labor Cost

#### 5.2.3 Manufacturing Expenses

### 5.3 Manufacturing Process Analysis of Antitumor Drugs of Alkylating Agent Class

## **6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

### 6.1 Antitumor Drugs of Alkylating Agent Class Industrial Chain Analysis

### 6.2 Upstream Raw Materials Sourcing

6.3 Raw Materials Sources of Antitumor Drugs of Alkylating Agent Class Major Players/Manufacturers in 2016

### 6.4 Downstream Buyers



## **7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

### **7.1 Marketing Channel**

#### **7.1.1 Direct Marketing**

#### **7.1.2 Indirect Marketing**

#### **7.1.3 Marketing Channel Development Trend**

### **7.2 Market Positioning**

#### **7.2.1 Pricing Strategy**

#### **7.2.2 Brand Strategy**

#### **7.2.3 Target Client**

### **7.3 Distributors/Traders List**

## **8 MARKET EFFECT FACTORS ANALYSIS**

### **8.1 Technology Progress/Risk**

#### **8.1.1 Substitutes Threat**

#### **8.1.2 Technology Progress in Related Industry**

### **8.2 Consumer Needs/Customer Preference Change**

### **8.3 Economic/Political Environmental Change**

## **9 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ALKYLATING AGENT CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)**

### **9.1 Global and Japan Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD) Forecast (2017-2022)**

### **9.2 Global and Japan Antitumor Drugs of Alkylating Agent Class Sales () Forecast by Type (2017-2022)**

#### **9.2.1 by Alkylating Agent Class**

#### **9.2.2 by**

### **9.3 Global and Japan Antitumor Drugs of Alkylating Agent Class Sales () Forecast by Application (2017-2022)**

### **9.4 Global and Japan Antitumor Drugs of Alkylating Agent Class Sales () Forecast by Regions (2017-2022)**

## **10 RESEARCH FINDINGS AND CONCLUSION**

## **11 METHODOLOGY AND DATA SOURCE**

## 11.1 Methodology/Research Approach

### 11.1.1 Research Programs/Design

### 11.1.2 Market Size Estimation

### 11.1.3 Market Breakdown and Data Triangulation

## 11.2 Data Source

### 11.2.1 Secondary Sources

### 11.2.2 Primary Sources

## 11.3 Disclaimer

## 11.4 Author List

## List Of Tables

### LIST OF TABLES AND FIGURES

Figure Product Picture of Antitumor Drugs of Alkylating Agent Class

Table Japan Antitumor Drugs of Alkylating Agent Class Sales (Million Units)

Comparison by Applications (2012-2017)

Figure Japan Sales Market Share (%) of Antitumor Drugs of Alkylating Agent Class by Applications in 2016

Table Global Antitumor Drugs of Alkylating Agent Class Sales (Million Units)

Comparison by Applications (2012-2017)

Figure Global Sales Market Share (%) of Antitumor Drugs of Alkylating Agent Class by Applications in 2016

Figure Department of Oncology Examples

Table Key Downstream Customer in Department of Oncology

Figure Department of Chemotherapy Examples

Table Key Downstream Customer in Department of Chemotherapy

Figure Pharmacology Examples

Table Key Downstream Customer in Pharmacology

Figure Bendamustine Product Picture

Figure Mizolastine Product Picture

Figure Busulfan Product Picture

Figure Embichine Product Picture

Figure Dacarbazine Product Picture

Figure Product Picture

Figure Product Picture

Table OHARA Pharmaceutical Co.,Ltd. Basic Information List

Table OHARA Pharmaceutical Co.,Ltd. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table OHARA Pharmaceutical Co.,Ltd. Antitumor Drugs of Alkylating Agent Class Sales Growth Rate (%) (2012-2017)

Table OHARA Pharmaceutical Co.,Ltd. Antitumor Drugs of Alkylating Agent Class Sales Market Share (%) in Japan (2012-2017)

Figure OHARA Pharmaceutical Co.,Ltd. Antitumor Drugs of Alkylating Agent Class Revenue Market Share (%) in Japan (2012-2017)

Table Kyowa Hakko Kirin Co.,Ltd Basic Information List

Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Alkylating Agent Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Alkylating Agent Class Sales

Growth Rate (%)(2012-2017)

Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Alkylating Agent Class Sales  
Market Share (%) in Japan (2012-2017)

Figure Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Alkylating Agent Class Revenue  
Market Share (%) in Japan (2012-2017)

Table Eisai Co., Ltd. Basic Information List

Table Eisai Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue  
(Million USD), Price () and Gross Margin (%)(2012-2017)

Table Eisai Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales Growth Rate  
(%)(2012-2017)

Table Eisai Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales Market Share (%)  
in Japan (2012-2017)

Figure Eisai Co., Ltd. Antitumor Drugs of Alkylating Agent Class Revenue Market Share  
(%) in Japan (2012-2017)

Table Mitsubishi Tanabe Pharma Corporation Basic Information List

Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Alkylating Agent  
Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Alkylating Agent  
Class Sales Growth Rate (%)(2012-2017)

Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Alkylating Agent  
Class Sales Market Share (%) in Japan (2012-2017)

Figure Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Alkylating Agent  
Class Revenue Market Share (%) in Japan (2012-2017)

Table Aspen Japan K.K. Basic Information List

Table Aspen Japan K.K. Antitumor Drugs of Alkylating Agent Class Sales (), Revenue  
(Million USD), Price () and Gross Margin (%)(2012-2017)

Table Aspen Japan K.K. Antitumor Drugs of Alkylating Agent Class Sales Growth Rate  
(%)(2012-2017)

Table Aspen Japan K.K. Antitumor Drugs of Alkylating Agent Class Sales Market Share  
(%) in Japan (2012-2017)

Figure Aspen Japan K.K. Antitumor Drugs of Alkylating Agent Class Revenue Market  
Share (%) in Japan (2012-2017)

Table Nippon Shinyaku Co., Ltd. Basic Information List

Table Nippon Shinyaku Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales (),  
Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Table Nippon Shinyaku Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales  
Growth Rate (%)(2012-2017)

Table Nippon Shinyaku Co., Ltd. Antitumor Drugs of Alkylating Agent Class Sales  
Market Share (%) in Japan (2012-2017)

Figure Nippon Shinyaku Co., Ltd. Antitumor Drugs of Alkylating Agent Class Revenue Market Share (%) in Japan (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Antitumor Drugs of Alkylating Agent Class

Figure Manufacturing Process Analysis of Antitumor Drugs of Alkylating Agent Class

Figure Antitumor Drugs of Alkylating Agent Class Industrial Chain Analysis

Table Raw Materials Sources of Antitumor Drugs of Alkylating Agent Class Major Players/Manufacturers in 2016

Table Major Buyers of Antitumor Drugs of Alkylating Agent Class

Table Distributors/Traders List

Figure Japan Antitumor Drugs of Alkylating Agent Class Sales (¥) and Growth Rate (%) Forecast (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Price (¥) Trend Forecast (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Sales (¥) and Growth Rate (%) Forecast (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Price (¥) Trend Forecast (2017-2022)

Table Japan Antitumor Drugs of Alkylating Agent Class Sales (¥) Forecast by Type (2017-2022)

Table Global Antitumor Drugs of Alkylating Agent Class Sales (¥) Forecast by Type (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Sales (¥) Forecast by Type (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Sales (¥) Forecast by Type (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Sales Volume Market Share Forecast by Type in 2017

Figure Global Antitumor Drugs of Alkylating Agent Class Sales Volume Market Share Forecast by Type in 2017

Table Japan Antitumor Drugs of Alkylating Agent Class Sales (¥) Forecast by Application (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Sales Volume Market Share

Forecast by Application (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Sales Volume Market Share

Forecast by Application in 2017

Table Global Antitumor Drugs of Alkylating Agent Class Sales () Forecast by Application (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Sales Volume Market Share

Forecast by Application (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Sales Volume Market Share

Forecast by Application in 2017

Table Japan Antitumor Drugs of Alkylating Agent Class Sales () Forecast by Regions (2017-2022)

Table Japan Antitumor Drugs of Alkylating Agent Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Japan Antitumor Drugs of Alkylating Agent Class Sales Volume Share Forecast by Regions (2017-2022)

Table Global Antitumor Drugs of Alkylating Agent Class Sales () Forecast by Regions (2017-2022)

Table Global Antitumor Drugs of Alkylating Agent Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Global Antitumor Drugs of Alkylating Agent Class Sales Volume Share Forecast by Regions (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: 2017-2022 Global and Japan Antitumor Drugs of Alkylating Agent Class Market Analysis Report

Product link: <https://marketpublishers.com/r/22F80C35FC5EN.html>

Price: US\$ 3,085.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/22F80C35FC5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

